Felix Health
Series B in 2023
Felix Health Inc. is a Canadian company established in 2019 and headquartered in Toronto. It operates an online prescription platform that provides medications for conditions such as erectile dysfunction, hair loss, acne, and birth control. The company aims to modernize healthcare in Canada by offering a seamless and straightforward experience for patients seeking treatment for various health concerns. Through its innovative approach, Felix Health addresses the needs of contemporary consumers in the healthcare sector.
Ukko Agro
Seed Round in 2021
Ukko Agro is a Toronto-based company that develops a smart agricultural ecosystem designed to optimize pesticide usage and minimize crop losses. Founded in 2017, the company provides technology tools that facilitate efficient on-farm decision-making with minimal time investment from growers. Its ecosystem employs prescriptive models for disease and pest management and integrates seamlessly with external on-farm machinery through the Internet of Things (IoT). By enabling real-time monitoring and predictive analytics, Ukko Agro helps farmers optimize crop inputs, reduce losses, and ultimately achieve higher yields. The company is committed to enhancing sustainability in agriculture by tracking, analyzing, and quantifying the benefits of optimized pesticide use.
Qvella
Venture Round in 2021
Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.
Felix Health
Series A in 2021
Felix Health Inc. is a Canadian company established in 2019 and headquartered in Toronto. It operates an online prescription platform that provides medications for conditions such as erectile dysfunction, hair loss, acne, and birth control. The company aims to modernize healthcare in Canada by offering a seamless and straightforward experience for patients seeking treatment for various health concerns. Through its innovative approach, Felix Health addresses the needs of contemporary consumers in the healthcare sector.
Qvella
Venture Round in 2020
Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.
Qvella
Venture Round in 2019
Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.
Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.
Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.
Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.